- The Oligonucleotide Therapeutics Society held its annual meeting this September in Denmark
- ISIS (Click for research page), ALNY (Click for research page), and TKMR (Click for research page) made numerous presentations, including those by Regulus, a joint venture of ISIS and ALNY. I also will note significant presentations by competing company Santaris, the defendant in a recent patent infringement lawsuit filed by Isis.
- Click here for PDF with all available abstracts from the conference.
- Check out info on presentations by BiotechDueDiligence companies at other scientific conferences on the Upcoming Events and Past Events pages.
- Detailed info on the presentations can be found below the jump:
0 Comments
--SYNERGY is primary registrational trial for cusirsen OGX-011, enrollment is moving along very nicely q&a session: --survival correlation w/ clusterin levels- what creates resistance to clusterin? what happens in nonresponsive tumors? Think about herceptin and HER2 expression. It doesn't matter so much where patients started. Clusterin is upregulated in repsonse to stress of treatment - we are trying to prevent the upregulation --We are not exploring a diagnostic yet, data on clusterin levels is more to supplement the regulatory package |
Categories
All
Archives
January 2020
|